Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (461-470 of 501) with videos related to

Pageof 51
Sort By:
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Journal of Hepatology|July 30, 2010
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individualsEric J Gowans, Stuart Roberts, Kathryn Jones, et al.
Urology|July 3, 2023
Longitudinal Changes in the Operative Experience for Junior Urology ResidentsEzra J Margolin, Daniel Schoenfeld, Caleb H Miles, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Pageof 51

Showing results (461-470 of 501) with videos related to

Sort By:
Pageof 51
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Journal of Hepatology|July 30, 2010
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individualsEric J Gowans, Stuart Roberts, Kathryn Jones, et al.
Urology|July 3, 2023
Longitudinal Changes in the Operative Experience for Junior Urology ResidentsEzra J Margolin, Daniel Schoenfeld, Caleb H Miles, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Internal Medicine Journal|January 12, 2017
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupDipti Talaulikar, Constantine S Tam, Douglas Joshua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Pageof 51